Stock Price Movement and Market Context
On 28 Nov 2025, Sandu Pharmaceuticals' share price touched an intraday low of Rs.37.01, representing a fall of 3.85% for the day. This decline followed two consecutive days of gains, signalling a reversal in short-term momentum. The stock underperformed its sector by 3.53% on the same day, trading below all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward pressure on the stock.
In contrast, the broader market showed resilience, with the Sensex opening flat and advancing marginally by 0.04% to 85,755.55 points. The benchmark index remains close to its 52-week high of 86,055.86, supported by mega-cap stocks and bullish moving average alignments. This divergence highlights the relative weakness of Sandu Pharmaceuticals compared to the overall market trend.
Historical Performance and Valuation Metrics
Over the past year, Sandu Pharmaceuticals has recorded a total return of -34.46%, significantly lagging behind the Sensex's 8.49% gain during the same period. The stock's 52-week high was Rs.62.80, underscoring the extent of the recent decline. This performance is consistent with the company's track record of underperformance against the BSE500 index over the last three annual periods.
From a valuation standpoint, the stock trades at a price-to-book value of 0.9, which is below the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector. This discount reflects market concerns about the company’s financial health and growth prospects.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Financial Indicators and Profitability Trends
Sandu Pharmaceuticals’ long-term financial indicators reveal modest returns and constrained growth. The company’s average Return on Equity (ROE) stands at 3.73%, which is relatively low for the sector. Net sales have expanded at an annual rate of 4.69% over the past five years, while operating profit has grown at 17.92% annually during the same period. These figures suggest limited momentum in revenue generation and profitability enhancement.
Debt servicing capacity remains a concern, with an average EBIT to interest ratio of 1.92, indicating a narrow margin to cover interest expenses. This ratio points to potential vulnerabilities in managing financial obligations, which may weigh on investor confidence.
Quarterly results for March 2025 showed net sales at Rs.14.07 crores, marking the lowest quarterly sales figure recorded recently. Despite this, the company’s profits have shown a rise of 10.9% over the past year, contributing to a PEG ratio of 2.2. This mixed financial picture reflects challenges in top-line growth alongside some improvement in profitability.
Shareholding and Market Position
The majority of Sandu Pharmaceuticals’ shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company operates within the Pharmaceuticals & Biotechnology sector, which has generally demonstrated stronger performance relative to Sandu Pharmaceuticals’ stock.
Given the stock’s current position below all major moving averages and its recent 52-week low, the market assessment reflects caution regarding the company’s near-term prospects.
Sandu Pharmaceuticals or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Comparative Sector and Market Analysis
While Sandu Pharmaceuticals has faced a decline of 34.46% over the last year, the Pharmaceuticals & Biotechnology sector has generally maintained steadier performance. The Sensex’s proximity to its 52-week high and its positive trajectory supported by mega-cap stocks contrasts with the stock’s downward trend. This divergence underscores the specific challenges faced by Sandu Pharmaceuticals within its industry context.
The stock’s trading below all key moving averages further emphasises the prevailing bearish sentiment. The 5-day, 20-day, 50-day, 100-day, and 200-day moving averages all remain above the current price level, indicating that the stock has yet to regain upward momentum in the short, medium, and long term.
Despite the subdued price action, the company’s valuation metrics suggest it is trading at a discount relative to its peers, which may reflect the market’s cautious stance on its financial and operational outlook.
Summary of Key Financial and Market Data
To summarise, Sandu Pharmaceuticals’ stock has reached a fresh 52-week low of Rs.37.01, with a day’s decline of 3.85%. The stock’s one-year return stands at -34.46%, contrasting with the Sensex’s positive 8.49% over the same period. The company’s average ROE is 3.73%, with net sales growing at 4.69% annually over five years and operating profit at 17.92%. The EBIT to interest coverage ratio averages 1.92, indicating limited debt servicing capacity. The stock trades below all major moving averages and at a price-to-book value of 0.9, reflecting a valuation discount within its sector.
These factors collectively illustrate the challenges Sandu Pharmaceuticals faces in regaining market confidence and improving its financial standing amid a competitive sector environment.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
